Melanoma patients showed intracranial responses when they received both a BRAF and MEK inhibitor.
All articles by Alexander M. Castellino
Intracranial and extracranial responses were provided with combination immunotherapy with nivolumab and ipilimumab, for patients with melanoma and brain metastases.
Talimogene laherparepvec along with ipilimumab improves the overall response rate over just ipilimumab among patients with unresected, advanced melanoma.
Latest News Your top articles for FridayFor More Personalized News
Haymarket Medical NetworkTop Picks
Continuing Medical Education (CME/CE) Courses